Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
Healthcare · Biological Products, (No Diagnostic Substances)
AI confidence 70% · prior close shown (market closed)
Inhibikase Therapeutics, Inc. shows recovering business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 5d ago
IKT's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on IKT.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Inhibikase Therapeutics, Inc. (IKT) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
IKT's AI investment thesis
Upgrade to Premium for IKT's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$2.15
Market cap
$300.00M
Profitable
No
Revenue $79,570.00
Net income
$-4.60M
FY Sep 15, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Healthcare · Biological Products, (No Diagnostic Substances)
Investment Snapshot above is the primary AlphaOS analysis for Inhibikase Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Inhibikase Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.